Research fellow at the Dana-Farber Cancer Institute and Harvard Medical School. Computational immunology / Spatial transcriptomics

Boston, MA
Excited to share our latest study published in @CellCellPress !! We uncovered that a single oncolytic virus injection can ignite deep, persistent T cell immunity in glioblastoma, lasting months to years. sciencedirect.com/science/ar…
4
33
146
9,697
Meet Maxime Meylan, PhD, a 2026 Parker Bridge Fellow and Instructor in Immunology at @DanaFarber Cancer Institute. Maxime studies how the organization of the tumor microenvironment shapes antitumor immune responses and determines whether T cells can effectively reach and eliminate cancer cells. His current research focuses on how tumor cell states and spatial tissue organization create barriers to T-cell infiltration in triple-negative breast cancer, to identify strategies to overcome immune exclusion. We’re proud to support Maxime and the next generation of cancer immunotherapy leaders pursuing bold ideas to transform cancer treatment. Learn more here: parkerici.org/the-latest/pic…
2
5
780
Excited to share that I’ve been selected as a 2026 Parker Bridge Fellow! This award will be incredibly valuable as I transition toward independence and build my own research program. I’m very grateful to PICI for their support at such an important stage of my career.
Today, PICI announced its 2026 class of Early Career Researchers awardees. The investigators will receive more than $1 million in combined funding to advance innovative research projects that could help shape the next generation of cancer immunotherapies. Meet the 2026 Early Career Researcher Awardees: 🔬 Sophie Louise Gray-Gaillard, @PennMedicine 🔬 Jingya Qiu, PhD, @GladstoneInst 🔬 Xinyu Xiang, @StanfordMed 🔬 Shaobo Yang, PhD, @DanaFarber 🔬 Maxime Meylan, PhD, @DanaFarber From programmable bacterial “living medicines” and tumor-targeting T-cell therapies to new approaches for understanding the tumor microenvironment and detecting cancer earlier, these researchers are pursuing high-risk, high-reward science with the potential to transform cancer treatment. Now in its 10th year, PICI’s Early Career Researcher Awards program has invested $23.9 million across 63 research projects, giving emerging scientists the funding, resources and collaborative network to turn bold ideas into breakthroughs. Learn more here: parkerici.org/the-latest/pic…
1
9
501
I’m at @AACR, catch me at the poster session! abstract #7743 #GBM #spatial
4
148
Maxime Meylan retweeted
Excited to share- Building on our work defining TRMacs heterogeneity, we show that distinct chemokine+ IM subsets and recruited TAM niches shape pro- and anti-tumor immunity within to the TME, while Ag+ moDCs trafficking to LNs dampen DC-based neoAg vac nature.com/articles/s41590-0…
4
28
110
7,118
PICI researcher Kai Wucherpfennig, MD, PhD, of @DanaFarber’s research shows a single injection of an oncolytic virus can trigger lasting T cell immunity against glioblastoma. Read more about the study and its impact here: bit.ly/4suBcRe
4
15
1,694
Nice summary of our study by @ACIR_org ! Read it here : shorturl.at/jj4Vj
6
226
Maxime Meylan retweeted
A new study led by @DanaFarber’s Dr. Kai Wucherpfennig and colleagues shows that an injection of a genetically modified virus that selectively infects and destroys cancer cells can recruit immune cells to penetrate and persist deep within brain tumors. ➡️ bit.ly/4atTuee
2
14
59
5,750
Maxime Meylan retweeted
🚨Paper alert 🚨 Check out our latest paper: We identified SPP1 as a key regulator of mesenchymal cell fate. Together with GREM1, SPP1 regulates reciprocal epithelial and mesenchymal PDAC cell fate. 📚Read more about this @Nature paper below ⬇️: nature.com/articles/s41586-0…
2
22
94
7,662
💯
My guidelines for exploratory data analysis
3
184
In a new Science study, researchers report that cancer cells can be reprogrammed in vivo into dendritic cells that can activate T cells and promote antitumor immunity. Learn more ⬇️ 📄: bit.ly/4eS9Y0L #SciencePerspective: bit.ly/4eUiHPW
16
147
486
56,529
Maxime Meylan retweeted
I haven’t posted much since Twitter is X, but I have a good reason today☺️ if you like #cancerstemcells #stemcells and #immunotherapy, this is for you! With partner in crime Phoenix Miao😎 nature.com/articles/s41568-0…
5
21
119
11,080
Exiting new method, looking forward to trying it!
Very excited to present STAMP: An Interpretable spatially aware dimension reduction of spatial transcriptomics nature.com/articles/s41592-0…
1
3
645
Maxime Meylan retweeted
Happy publication day for us! Labor of love with @CoffmanLab #TLS #ovariancancer @UPMCHillmanCC @PittTweet The activity of tertiary lymphoid structures in high grade serous ovar... sciencedirect.com/science/ar…
10
15
70
5,648
Maxime Meylan retweeted
CAST enables physical alignment of spatial omics data across replicates, techs, modalities at single-cell resolution. Such accurate alignment enables spatial atlas searching, unbiased DEG identification, and reconstruction of spatial multi-omics. DM for questions and collabs!
With the growing availability of spatial omics data from different techniques, CAST offers a computational tool for reconstructing single-cell multi-omic profiles and downstream analysis in a spatially resolved manner. @WangXiaoLab nature.com/articles/s41592-0…
4
32
127
51,191